Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Andrés José Maria Ferreri,Kate Cwynarski,Elisa Jacobsen Pulczynski,Maurilio Ponzoni,Martina Deckert,Letterio S. Politi,Valter Torri,Christopher P. Fox,Paul La Rosée,Elisabeth Schorb,Achille Ambrosetti,Alexander Röth,Claire Hemmaway,Angela Ferrari,Kim Linton,Roberta Rudà,Mascha Binder,Tobias Pukrop,Monica Balzarotti,Alberto Fabbri,Peter Johnson,Jette Sønderskov Gørløv,Georg Hess,Jens Panse,Francesco Pisani,Alessandra Tucci,Stephan Stilgenbauer,Bernd Hertenstein,Ulrich Keller,Stefan W. Krause,Alessandro Levis,Hans J. Schmoll,Franco Cavalli,Jürgen Finke,Michele Reni,Emanuele Zucca,Gerald Illerhaus +36 more
TLDR
The IELSG32 trial provides a high level of evidence supporting the use of MATRix combination as the new standard chemoimmunotherapy for patients aged up to 70 years with newly diagnosed primary CNS lymphoma and as the control group for future randomised trials.About:
This article is published in The Lancet Haematology.The article was published on 2016-05-01 and is currently open access. It has received 391 citations till now. The article focuses on the topics: Chemoimmunotherapy & ThioTEPA.read more
Citations
More filters
Journal ArticleDOI
Primary CNS Lymphoma
TL;DR: This review will give an overview of the presentation, evaluation, and treatment of immunocompetent patients with PCNSL.
Journal ArticleDOI
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial
Andrés José Maria Ferreri,Kate Cwynarski,Elisa Jacobsen Pulczynski,Christopher P. Fox,Elisabeth Schorb,Paul La Rosée,Mascha Binder,Alberto Fabbri,Valter Torri,Eleonora Minacapelli,Monica Falautano,Fiorella Ilariucci,Achille Ambrosetti,Alexander Röth,Claire Hemmaway,Peter Johnson,Kim Linton,Tobias Pukrop,Jette Sønderskov Gørløv,Monica Balzarotti,Georg Hess,Ulrich Keller,Stephan Stilgenbauer,Jens Panse,Alessandra Tucci,Lorella Orsucci,Francesco Pisani,Alessandro Levis,Stefan W. Krause,Hans J. Schmoll,Bernd Hertenstein,Mathias J. Rummel,Jeffery Smith,Michael Pfreundschuh,Giuseppina Cabras,Francesco Angrilli,Maurilio Ponzoni,Martina Deckert,Letterio S. Politi,Juergen Finke,Michele Reni,Franco Cavalli,Emanuele Zucca,Gerald Illerhaus +43 more
TL;DR: The results of the second randomisation that addresses the efficacy of myeloablative chemotherapy supported by autologous stem-cell transplantation (ASCT) as an alternative to whole-brain radiotherapy (WBRT) as consolidation after high-dose-methotrexate-based chemoimmunotherapy were reported.
Journal ArticleDOI
Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
Upton Allen,Jutta K. Preiksaitis +1 more
TL;DR: These updated guidelines from the American Society of Transplantation Infectious Diseases Community of Practice review the diagnosis, management, and prevention of post‐transplant lymphoproliferative disorders (PTLD) and other Epstein‐Barr virus (EBV) syndromes after solid organ transplantation.
Journal ArticleDOI
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Jacoline E C Bromberg,Samar Issa,Katerina Bakunina,Monique C. Minnema,Tatjana Seute,Marc Durian,Gavin Cull,Gavin Cull,Harry C. Schouten,Wendy Stevens,Josée M. Zijlstra,Joke W. Baars,Marcel Nijland,Kylie D. Mason,Aart Beeker,Martin J. van den Bent,Max Beijert,Michael Gonzales,Daphne de Jong,Jeanette K. Doorduijn +19 more
TL;DR: This intergroup, multicentre, open-label, randomised phase 3 study aimed to investigate the addition of rituximab to a high-dose methotrexate-based chemotherapy regimen in patients with newly diagnosed primary CNS lymphoma.
Journal ArticleDOI
The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades.
Joe S. Mendez,Quinn T. Ostrom,Haley Gittleman,Carol Kruchko,Lisa M. DeAngelis,Lisa M. DeAngelis,Jill S. Barnholtz-Sloan,Christian Grommes,Christian Grommes +8 more
TL;DR: The poor outcome seen in the particularly vulnerable elderly patient population highlights the need for clinical trials targeting the elderly in hopes of improving treatment strategies and survival.
References
More filters
Journal ArticleDOI
Revised response criteria for malignant lymphoma
Bruce D. Cheson,Beate Pfistner,Malik E. Juweid,Randy D. Gascoyne,Lena Specht,Sandra J. Horning,Bertrand Coiffier,Richard I. Fisher,Anton Hagenbeek,Emanuele Zucca,Steven T. Rosen,Sigrid Stroobants,T. Andrew Lister,Richard T. Hoppe,Martin Dreyling,Kensei Tobinai,Julie M. Vose,Joseph M. Connors,Massimo Federico,Volker Diehl +19 more
TL;DR: New guidelines incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma are presented and it is hoped that they will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
Journal ArticleDOI
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.
Andy Trotti,A. Dimitrios Colevas,Ann Setser,Valerie W. Rusch,David P. Jaques,Volker Budach,Corey J. Langer,Barbara A. Murphy,Richard Cumberlin,C. Norman Coleman,Philip Rubin +10 more
TL;DR: Recent progress in the evolution of adverse effects grading systems is updated and the development of CTCAE v3.0 is reviewed, which represents an international collaboration and consensus of the oncology research community.
Journal ArticleDOI
Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
Lauren E. Abrey,Tracy T. Batchelor,A. J. M. Ferreri,Mary Gospodarowicz,Elisa Jacobsen Pulczynski,Emanuele Zucca,Justine R. Smith,Agnieszka Korfel,Carole Soussain,Lisa M. DeAngelis,Edward A. Neuwelt,Brian P. O'Neill,Eckhard Thiel,Tamara Shenkier,Fransesc Graus,Martin J. van den Bent,John F. Seymour,Philip Poortmans,James O. Armitage,Franco Cavalli +19 more
TL;DR: An international group of experts meeting to review current standards of reporting and to formulate a consensus opinion regarding minimum baseline evaluation and common standards for assessing response to therapy hope that these guidelines will improve communication among investigators and comparability among clinical trials in a way that will allow to develop better therapies for patients.
Journal ArticleDOI
Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience
Andrés J.M. Ferreri,Jean-Yves Blay,Michele Reni,Felice Pasini,Michele Spina,Achille Ambrosetti,A. Calderoni,Andrea Rossi,V. Vavassori,Annarita Conconi,Liliana Devizzi,Françoise Berger,Maurilio Ponzoni,Bettina Borisch,Marianne Tinguely,Michele Cerati,Mario Milani,Enrico Orvieto,JG Sanchez,Christine Chevreau,Stefania Dell'Oro,Emanuele Zucca,Franco Cavalli +22 more
TL;DR: Age, PS, LDH serum level, CSF protein concentration, and involvement of deep structures of the brain were independent predictors of survival and a prognostic score including these five parameters seems advisable in distinguishing different risk groups in PCNSL patients.
Journal ArticleDOI
Treatment for Primary CNS Lymphoma: The Next Step
TL;DR: Increasing the dose of MTX and adding procarbazine and vincristine improved disease control and overall survival in patients with newly diagnosed PCNSL and younger patients in particular fared extremely well with this treatment regimen.
Related Papers (5)
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Andrés J.M. Ferreri,Michele Reni,Marco Foppoli,Maurizio Martelli,Gerasimus A. Pangalis,Maurizio Frezzato,Maria Giuseppina Cabras,Alberto Fabbri,Gaetano Corazzelli,Fiorella Ilariucci,Giuseppe Rossi,Riccardo Soffietti,Caterina Stelitano,Daniele Vallisa,Francesco Zaja,Lucia Zoppegno,Gian Marco Aondio,Giuseppe Avvisati,Monica Balzarotti,Alba A. Brandes,José Luis Crespo Fajardo,Henry L. Gomez,Attilio Guarini,Graziella Pinotti,Luigi Rigacci,Catrina Uhlmann,Piero Picozzi,Paolo Vezzulli,Maurilio Ponzoni,Emanuele Zucca,Federico Caligaris-Cappio,Franco Cavalli +31 more
Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
Lauren E. Abrey,Tracy T. Batchelor,A. J. M. Ferreri,Mary Gospodarowicz,Elisa Jacobsen Pulczynski,Emanuele Zucca,Justine R. Smith,Agnieszka Korfel,Carole Soussain,Lisa M. DeAngelis,Edward A. Neuwelt,Brian P. O'Neill,Eckhard Thiel,Tamara Shenkier,Fransesc Graus,Martin J. van den Bent,John F. Seymour,Philip Poortmans,James O. Armitage,Franco Cavalli +19 more
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
Eckhard Thiel,Agnieszka Korfel,Peter Martus,Lothar Kanz,Frank Griesinger,Michael Rauch,Alexander Röth,Bernd Hertenstein,Theda von Toll,Thomas Hundsberger,H. Mergenthaler,Malte Leithäuser,Tobias Birnbaum,Lars Fischer,Kristoph Jahnke,Ulrich Herrlinger,Ludwig Plasswilm,Thomas Nägele,Torsten Pietsch,Michael Bamberg,Michael Weller,Michael Weller +21 more